Mapmygenome to raise $20 million

Mapmygenome, the molecular diagnostics and predictive health analytics firm, is in the process of concluding a deal to raise $20 million in the next three months.

The Hyderabad-based start-up with 30 employees will use the proceeds for international expansion and sales and marketing. “Part of the proceeds will be used to upgrade infrastructure to improve our analytics capabilities,” Anu Acharya, Chief Executive Officer of Mapmygenome, told BusinessLine .

The company is looking to expand to Latin America, South-East Asia and the Gulf countries, besides extending services to top Indian cities. “We are going to launch our services in those geographies this financial year through our partners. There is a huge interest in India and in these locations abroad for molecular-based diagnostics and predictive solutions,” she said.

The firm has come out with Genomepatri Lite, a lighter version of its flagship product Genomepatri. Priced at ₹15,000, this lighter version throws light on people’s genetic predisposition to lifestyle, metabolic, cardiovascular, ocular, skin and hair, orthopaedic, gastro, and gender specific conditions.

“Some people might not be interested to have the full range tests that Genomepatri offers. They still may be interested to know how their lifestyle could lead to certain problems. This Lite version would provide that. And, this can be quickly upgradable to the higher version,” she said.

The firm segregated over 100 traits, diseases, drug responses, and inherited conditions featured in Genomepatri into 16 panels. “Genomepatri Lite offers eight of the panels. Each of these services and Genomepatri Lite are upgradable to the full service,” she said.

Based on the test results, Mapmygenome counsellors suggest steps to people on how to reduce the risks by modifying lifestyle.

COMMENT NOW